Perez Nicholas, O., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., Myer, L., Waitt, C., Reynolds, H., and Khoo, S.
Evidence on safety and health related quality of life outcomes is needed for rollout of new antiretroviral therapies. Results After 24weeks postpartum, significant improvements were seen in dolutegravir-treatment; PHS-scores (11.9±1.4, P<0.001); MHS-scores (10.7±1.7, P<0.001) and efavirenz-treatment; PHS-scores (9±1.1, P<0.001); MHS-scores (6.7, P<0.001) groups. After 48weeks postpartum, increase in PHS-scores and MHS-scores remained significant in both treatment-groups but were not significantly different between-groups (PHS: 1.1±1.0, P=0.269, MHS: -0.8±1.6, P=0.606). [Extracted from the article]